The average one-year price target for Q32 Bio (NasdaqCM:QTTB) has been revised to $11.56 / share. This is an increase of 13.33% from the prior estimate of $10.20 dated November 7, 2025.
The price target is an average of many targets provided by analysts. The latest targets range from a low of $4.04 to a high of $21.00 / share. The average price target represents an increase of 435.18% from the latest reported closing price of $2.16 / share.
What is the Fund Sentiment?
There are 107 funds or institutions reporting positions in Q32 Bio. This is an decrease of 31 owner(s) or 22.46% in the last quarter. Average portfolio weight of all funds dedicated to QTTB is 0.02%, an increase of 26.32%. Total shares owned by institutions decreased in the last three months by 9.13% to 8,589K shares.
What are Other Shareholders Doing?
Orbimed Advisors holds 2,253K shares representing 18.47% ownership of the company. No change in the last quarter.
Atlas Venture Life Science Advisors holds 2,092K shares representing 17.15% ownership of the company. No change in the last quarter.
Carlyle Group holds 1,103K shares representing 9.04% ownership of the company. No change in the last quarter.
Acorn Capital Advisors holds 803K shares representing 6.59% ownership of the company. No change in the last quarter.
Arch Venture holds 320K shares representing 2.63% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
